Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160147 · ClinicalTrials.gov registry record · Phase 3
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00160147 is a Phase 3 study that was terminated before completion, run by Solvay Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00160147, a Phase 3 study, was terminated before completion, sponsored by Solvay Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
Interventions
- DRUG Placebo
- DRUG bifeprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160147
The ClinicalTrials.gov registry entry for NCT00160147 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00160147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160147 about?
NCT00160147 is a clinical study titled "Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type". This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
What is the current status of trial NCT00160147?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2005-12. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00160147?
The interventions under investigation include: Placebo (DRUG), bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00160147?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.